



# PHARMENABLE

unlocking innovative medicines

From academia to an AI drug discovery company



Dr Hannah Sore, Co-Founder and CEO

[PHARMENABLE.COM](https://pharmenable.com)



# THE POTENTIAL FOR A NEW GENERATION OF SMALL MOLECULE THERAPEUTIC MODALITIES

Replicate the specificity of biologics in the powerful and scalable form of a **small molecule**



## SMALL MOLECULES

## BIOLOGICS

	SMALL MOLECULES	BIOLOGICS
<b>Structure</b>	✓ Small, simple	✗ Large, complex
<b>Manufacturing</b>	✓ Easy, cheap	✗ Challenging, costly
<b>Stability</b>	✓ Excellent	✗ Limited
<b>Method of administration</b>	✓ Oral	✗ IV
<b>Distribution</b>	✓ Easy	✗ Difficult
<b>Location of action</b>	✓ Not limited	✗ Only extracellular (20%)
<b>Selectivity (promiscuous)</b>	✗ Low selectivity	✓ High selectivity



# CHALLENGING TARGETS NEED ACCESS TO NEW AND DIVERSE AREAS OF THE CHEMICAL SPACE

The number of possible “drug-like” small molecules

# ASTRONOMIC!

# $10^{62}$

TARGET 1



NEW CHEMICAL SPACE  
REQUIRED

TARGET 4

TARGET 3

SCREENING COLLECTION 1

SCREENING COLLECTION 2

TARGET 2

Diverse 3D-shaped small  
molecule collections

SCREENING COLLECTION 3



# OUR VISION: UNLOCKING CHEMICAL SPACE TO DELIVER INNOVATIVE NEW MEDICINES



**Dr Jelena Aleksic**  
(Founder, CBO)



**Dr Hannah Sore**  
(Founder, CEO)




**Dr Natalia Mateu**  
(Founder, CSO)



**Why are you doing it?**  
**What do you want out of it?**




# PHARMENABLE'S JOURNEY TO ESTABLISHING A PROPRIETARY DRUG DISCOVERY PORTFOLIO



## DEVELOPING THE NEXT GENERATION SMALL MOLECULE DRUG DISCOVERY COMPANY





# PHARMENABLE

unlocking innovative medicines

BUILDING A PIPELINE OF  
INNOVATIVE MEDICINES

EXPLORING NEW AREAS OF  
CHEMICAL SPACE TO UNLOCK  
CHALLENGING TARGETS

HIGHLY EXPERIENCED AND  
WORLD CLASS TEAM

